This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

Study summary

The purpose of this study is to compare the efficacy of ZD6474 and ZD1839 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedZD6474 and Placebo

Plus 1 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 24, 2016 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?48 U.S. locations

Locations may change over time.

Who runs it?Genzyme, a Sanofi Company

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: Genzyme, a Sanofi Company
Interventions being studied: Drug: ZD6474; Drug: Placebo; Drug: ZD1839

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Treatment approach

Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Failure of either first-line and/or second-line chemotherapy either of which was platinum-based (the prior regimen must have failed the subject because of toxicity or progression of tumor
Prior histologic or cytologic confirmation of locally advanced or metastatic (IIIB/IV) NSCLC

Reasons someone may not be able to joinExclusion criteria

Subjects who have received second-line or subsequent chemotherapy
Any evidence of clinically active interstitial lung disease (patients with chronic, stable, radiographic changes who are asymptomatic, need not be excluded)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Research SitePine Bluff, Arkansas
Research SiteLos Angeles, California
Research SitePalm Springs, California
Research SiteSan Diego, California
Research SiteBoca Raton, Florida
Research SiteJacksonville, Florida
Research SiteOrange Park, Florida
Research SiteCoeur d'Alene, Idaho
Research SiteChicago, Illinois
Research SiteIndianapolis, Indiana
Research SiteShreveport, Louisiana
Research SiteSaint Loius, Missouri

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 24, 2016. Always confirm current availability with the study team.

View original record ↗